Leukotriene A₄ Hydrolase Is a Candidate Predictive Biomarker for Successful Allergen Immunotherapy.

ABSTRACT:

Background

Allergic rhinitis is a common disorder that affects 10% to 40% of the population worldwide. Allergen immunotherapy (AIT) represents the only therapy that has the potential to resolve clinical symptoms of allergic rhinitis. However, up to 30% of patients do not respond to AIT. Biomarkers predicting the clinical efficacy of AIT as early as possible would significantly improve the patient selection and reduce unnecessary societal costs.

Methods

Artemisia pollen allergic patients who received at least 1-year AIT were enrolled. Clinical responses before and after 1-year AIT were evaluated to determine AIT responders. Artemisia specific IgE and IgG4 levels were measured by using ImmunoCAP and enzyme-linked immunosorbent assay (ELISA) separately. Stepwise r

SUBMITTER: Ma TT 

PROVIDER: S-EPMC7732448 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature